MODAFINIL for Multiple sclerosis | Relapsing-remitting multiple sclerosis | Clinically isolated syndrome

Inclusion criteria

• {"criterion_text":"- Participant is willing and able to give informed consent for the participation in the trial\n- Participants, that in the medical investigator’s opinion, are able and willing to comply with all trial requirements.\n- Patients that are able to read and write\n- Male or female, aged between 18 and 64 years old at the time of signing the ICF\n- Diagnosed with Relapsing-Remitting MS or Clinically Isolated Syndrome, according to McDonald 2017 diagnostic criteria (Thompson et al., 2018).\n- Expanded disability status score (EDSS) less than 6.5.\n- Presence of subjective cognitive complaints\n- SDMT score (number of correct responses within 90 seconds) at Screening ≤ 55 (Benedict et al., 2016; Parmenter et al., 2007).\n- Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner use protocol’s recommended effective contraception methods, which is not based only on hormonal methods, during all the 6 months of the trial (3 months of treatment plus 3 months of safety follow-up).\n- Male participants must agree to refrain from donation of semen from first study treatment administration up to at least 90 days after last administration."}

Exclusion criteria

• {"criterion_text":"- Female participant who is pregnant, breastfeeding or planning pregnancy during the trial.\n- Positive test for anti-Human Immunodeficiency virus 1 or 2 antibodies, Hepatitis B surface antigen (HBsAg) or anti Hepatitis C virus antibodies.\n- Creatinine clearance < 20 ml/min determined by Cockcroft-Gault equation.\n- Participants who have participated in another research trial involving an investigational product within the past 5 half-lives of the other investigational product\n- History of alcoholism or drug abuse.\n- Average daily consumption of more than 20 cigarettes.\n- Participants with disability that interferes with the performance of the CT procedures (for example, motor deficit in upper limb, decreased visual acuity even with correction).\n- Participants with increased risk of epileptic seizures, history of cardiac arrhythmias, or uncontrolled moderate to severe hypertension.\n- Participants taking warfarin or any other prohibited medication.\n- Any other condition that, in the opinion of the investigator, contra-indicates the participation of the patient.\n- Participants who have any disability that, in the opinion of the investigator, significantly interferes with the neuropsychological testing and/or the tasks in the functional MRI\n- Significant neurological history aside from MS (e.g., Epilepsy).\n- Participants not able to undergo MRI scanning\n- Participants who have any contra-indication for taking modafinil, according to the prescribing information and SmPC, such as hypersensitivity to the active substance and any excipient present in the modafinil or any documented adverse reaction after modafinil intake\n- Participants with known hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption\n- Participants with a history of left ventricular hypertrophy or cor pulmonale and patients with mitral valve prolapse who developed mitral valve prolapse syndrome when previously treated with central nervous system stimulants\n- Current use of modafinil, armodafinil\n- Current use of other psychostimulants, including amphetamines, cocaine, bupropion, gingko biloba, among others, and beverages or food containing methylxanthines (e.g., coffee, tea, cola, caffeine, chocolate, sodas) exceeding 500 mg methylxanthines per day (for example, consumption of more than 5 espresso coffees or 100 mg of dark chocolate per day; Sanchez, 2017).\n- Sleep complaints confirmed by Epworth Sleepiness Scale (ESS) scale score >10 at screening visit OR known sleep disorder.\n- Significant psychiatric history (e.g., Schizophrenia, Bipolar Disorder, Major Depression, severe anxiety disorder, aggressive or hostile behaviour).\n- A documented history of attempted suicide in the last 2 years OR suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in the assessment of suicidal ideation on the C-SSRS) over the 6 months prior to the Screening Visit.\n- Significant insomnia (grade > 1 according to Common Terminology Criteria for Adverse Events, CTCAE v5).\n- History of severe hypersensitivity reactions to any medicine\n- Presence of any clinically significant abnormality in ECG morphology or ECG parameters\n- Known immunodeficiency syndrome\n- Have serum alanine aminotransferase (ALT) values greater than 3 times the upper limit of normal at screening"}

Primary endpoints

• {"endpoint_text":"- Changes in brain function and connectivity measured using resting state fMRI (at baseline and after 3 months of treatment with Modafinil). Functional MRI will be performed at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit).","definition_or_measurement_approach":"Measured using resting-state fMRI at baseline, before and 3h (±30 min) after Modafinil administration, and at the end of treatment (3-month visit); changes in brain function and connectivity assessed."}

Secondary endpoints

• {"endpoint_text":"- Changes in brain function and connectivity measured using a Go/no-Go task fMRI.","definition_or_measurement_approach":"Measured using task-based (Go/No-Go) fMRI at baseline, 3h (±30 min) after Modafinil administration, and at 3-month visit to assess task-related brain function and connectivity."}
• {"endpoint_text":"- Changes in patient reported outcomes (PROs) and neuropsychological tests - Perceived Deficits Questionnaire (PDQ), Symbol Digit Modalities Test (SDMT), Stroop test measured as interference index, MS-specific QoL questionnaire, Work Productivity and Activity Impairment Questionnaire for MS (WPAI:MS) and Modified Fatigue Impact Scale (MFIS). These assessments will occur in the screening or baseline visits and at the end of treatment (3-month visit).","definition_or_measurement_approach":"Assessed via PRO instruments and neuropsychological tests (PDQ, SDMT, Stroop interference index, MS-specific QoL, WPAI:MS, MFIS) at screening/baseline and at end of treatment (3-month visit)."}

Portugal

Earliest CTIS Part Ii Submission Date

19-05-2024

Latest Decision Or Authorization Date

18-03-2025

Processing Time Days

303

Number Of Sites

1

Number Of Participants

64

Primary sponsor

Full Name

CCAB Centro Clinico Academico Braga Associacao

Organisation Type

Pharmaceutical company

Country Of Registered Address

Portugal